Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Analysts Review
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, May 1, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding HCA Holdings, Inc. (NYSE: HCA), Express Scripts Inc. (NASDAQ: ESRX), Tenet Healthcare Corp. (NYSE: THC), Quest Diagnostics Inc. (NYSE: DGX) and Endo International PLC (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1814-100free.
HCA Holdings, Inc. Analyst Notes
On April 25, 2014, shares of the HCA Holdings, Inc. (HCA) rose 5.76% to end the trading session at $53.44. Wall Street Journal reported on April 25, 2014 that hospital shares moved up after two healthcare operators reported a better-than-expected impact from health-care reform. According to the article, two operators - Universal Health Services Inc. and LifePoint Hospitals Inc. - announced a positive impact of Medicaid expansion on their earnings driving down self-pay patients. The article further stated that shares of other healthcare service providers also rose on April 25, 2014 due to the positive impact from the health-care reform. HCA will host its Q1 2014 earnings call on April 29, 2014 at 9:00 am CT (10:00 am ET). The full analyst notes on HCA are available to download free of charge at:
Express Scripts Inc. Analyst Notes
On April 18, 2014, Express Scripts Inc. (Express Scripts) announced that it has been awarded the 7-year TRICARE Pharmacy Program, Fourth Generation (TPharm4) contract catering to nearly 10 million beneficiaries by the U.S. Department of Defense. The Company informed that the contract will include administering a retail pharmacy network, operating the TRICARE Mail Order Pharmacy and providing specialty pharmacy services with effect from May 1, 2015. Express Scripts' technical and administrative services are expected to expand under the TPharm4 contract, as the Company will serve the pharmacy needs of the military worldwide, comprising Military Treatment Facilities amongst others. The full analyst notes on Express Scripts are available to download free of charge at:
Tenet Healthcare Corp. Analyst Notes
On April 25, 2014, shares of Tenet Healthcare Corp.'s (Tenet) gained a whopping 9.13%, closing the trading session at $46.12 on high volumes. During the session, the Company's shares opened at $43.88 and fluctuated in the range of $43.68 - $46.49. According to an article on the Wall Street Journal, the Company's shares rose in response to the better-than-expected impact from health-care reform on earnings, reported by two healthcare operators. A total of 5.47 million shares changed hands during the session. Tenet is due to release its Q1 2014 financial results on May 5, 2014, after the market close. The full analyst notes on Tenet are available to download free of charge at:
Quest Diagnostics Inc. Analyst Notes
On April 24, 2014, shares of Quest Diagnostics Inc. (Quest Diagnostics) fell 2.94% to end the trading session at $55.58 after the Company reported Q1 2014 earnings, which missed analysts' estimates. The Company posted a decline of 2.3% YoY in its net revenues to $1.7 billion for Q1 2014. Net income came in at $104 million, or $0.72 per diluted share, as compared to $136 million, or $0.86 per diluted share, in Q1 2013. Q1 2014 adjusted diluted EPS from continuing operations was $0.84, versus $0.89 in 2013. According to Quest Diagnostics, adjusted diluted EPS was adversely impacted by approximately $0.11 due to unseasonably harsh winter. Analysts at Thomson Reuters had expected the Company to report earnings of $0.88 per share, on an average, for Q1 2014. Steve Rusckowski, President and CEO said that the Company will show positive revenue growth beginning Q2 2014. The full analyst notes on Quest Diagnostics are available to download free of charge at:
Endo International PLC Analyst Notes
On April 24, 2014, Endo International PLC (Endo) announced that its affiliates have acquired worldwide rights to Sumavel® DosePro® (sumatriptan injection) for subcutaneous use, a needle-free delivery system for sumatriptan, from Zogenix, Inc. for an upfront payment of $85 million and rights to additional cash payments contingent upon achieving certain commercial milestones. Sumavel DosePro is a prescription medicine given with a needle-free delivery system to treat adults who have been diagnosed with acute migraine or cluster headaches. Rajiv De Silva, President and CEO of Endo, said, "We are focused on completing a seamless transition of commercial support for this currently marketed product that will leverage our existing commercial expertise in pain and migraine management and the current infrastructure of our branded pharmaceuticals business overall." The Company expects this addition to be immediately accretive to adjusted diluted EPS. In addition, the product will be commercialized by current Endo Branded Pharmaceutical team. The full analyst notes on Endo are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.